These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 24251363)

  • 1. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacogenetic versus a clinical algorithm for warfarin dosing.
    Kimmel SE; French B; Kasner SE; Johnson JA; Anderson JL; Gage BF; Rosenberg YD; Eby CS; Madigan RA; McBane RB; Abdel-Rahman SZ; Stevens SM; Yale S; Mohler ER; Fang MC; Shah V; Horenstein RB; Limdi NA; Muldowney JA; Gujral J; Delafontaine P; Desnick RJ; Ortel TL; Billett HH; Pendleton RC; Geller NL; Halperin JL; Goldhaber SZ; Caldwell MD; Califf RM; Ellenberg JH;
    N Engl J Med; 2013 Dec; 369(24):2283-93. PubMed ID: 24251361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
    Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
    N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
    Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.
    Guo C; Kuang Y; Zhou H; Yuan H; Pei Q; Li J; Jiang W; Ng CM; Chen X; Huo Y; Cui Y; Wang X; Yu J; Sun X; Yu W; Chen P; Miao D; Liu W; Yu Z; Ouyang Z; Shi X; Lv C; Peng Z; Xiong G; Zeng G; Zeng J; Dai H; Peng J; Zhang Y; Xu F; Wu J; Chen X; Gong H; Yang Z; Wu X; Fang Q; Yang L; Li H; Tan H; Huang Z; Tang X; Yang Q; Tu S; Wang X; Xiang Y; Huang J; Wang X; Cai J; Jiang S; Huang L; Peng J; Gong L; Zou C; Yang G
    Circ Genom Precis Med; 2020 Aug; 13(4):e002602. PubMed ID: 32510984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
    Ferder NS; Eby CS; Deych E; Harris JK; Ridker PM; Milligan PE; Goldhaber SZ; King CR; Giri T; McLeod HL; Glynn RJ; Gage BF
    J Thromb Haemost; 2010 Jan; 8(1):95-100. PubMed ID: 19874474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials.
    Tse G; Gong M; Li G; Wong SH; Wu WKK; Wong WT; Roever L; Lee APW; Lip GYH; Wong MCS; Liu T;
    Br J Clin Pharmacol; 2018 Sep; 84(9):1868-1882. PubMed ID: 29704269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.
    Borgman MP; Pendleton RC; McMillin GA; Reynolds KK; Vazquez S; Freeman A; Wilson A; Valdes R; Linder MW
    Thromb Haemost; 2012 Sep; 108(3):561-9. PubMed ID: 22836303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.
    Anand A; Hegde NC; Chhabra P; Purohit J; Kumar R; Gupta A; Lad DP; Mohindra R; Mehrotra S; Vijayvergiya R; Kumar B; Sharma V; Malhotra P; Ahluwalia J; Das R; Patil AN; Shafiq N; Malhotra S
    Ann Hematol; 2024 Jun; 103(6):2133-2144. PubMed ID: 38634917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-guided dosing of warfarin.
    Mega JL; Giugliano RP
    Clin Chem; 2014 Jul; 60(7):920-2. PubMed ID: 24691686
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
    Eckman MH; Rosand J; Greenberg SM; Gage BF
    Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
    Patrick AR; Avorn J; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
    Linder MW; Bon Homme M; Reynolds KK; Gage BF; Eby C; Silvestrov N; Valdes R
    Clin Chem; 2009 Oct; 55(10):1861-8. PubMed ID: 19679631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.